STOCK TITAN

Eli Lilly (LLY) CFO Lucas Montarce receives 1,365-share stock award

Filing Impact
(Very High)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Montarce Lucas reported acquisition or exercise transactions in this Form 4 filing.

Eli Lilly & Co. executive vice president and chief financial officer Lucas Montarce reported receiving a stock award of 1,365.47 shares of common stock on February 9, 2026. The award was recorded at a price of $1,044.67 per share, bringing his directly held stake to 16,050.206 shares.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Montarce Lucas

(Last) (First) (Middle)
LILLY CORPORATE CENTER

(Street)
INDIANAPOLIS IN 46285

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ELI LILLY & Co [ LLY ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP & CFO
3. Date of Earliest Transaction (Month/Day/Year)
02/09/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/09/2026 A 1,365.47 A $1,044.67 16,050.206 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
Remarks:
/s/ Jonathan Groff for Lucas E. Montarce, pursuant to authorization on file 02/11/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Eli Lilly (LLY) report for EVP & CFO Lucas Montarce?

Eli Lilly reported that EVP & CFO Lucas Montarce received a stock award of 1,365.47 common shares. The transaction was coded as a grant or other acquisition, increasing his directly owned stake to 16,050.206 shares after the award.

Was the Eli Lilly (LLY) Lucas Montarce Form 4 a stock purchase or a grant?

The Form 4 shows a stock grant, not an open-market purchase. Transaction code A indicates a grant, award, or other acquisition, with 1,365.47 common shares added to Lucas Montarce’s directly held position as Eli Lilly’s executive vice president and chief financial officer.

At what price was Lucas Montarce’s Eli Lilly (LLY) stock award recorded?

The reported stock award to Lucas Montarce was recorded at $1,044.67 per share. This price is the value used for the 1,365.47 common shares granted on February 9, 2026, as disclosed in the Form 4 filing.

How many Eli Lilly (LLY) shares does Lucas Montarce own after this Form 4 transaction?

After the reported transaction, Lucas Montarce beneficially owns 16,050.206 Eli Lilly common shares directly. This total reflects his holdings following the grant of 1,365.47 additional shares reported on February 9, 2026 in the Form 4.

What is Lucas Montarce’s role at Eli Lilly (LLY) in this Form 4 filing?

In the Form 4, Lucas Montarce is identified as an officer of Eli Lilly, serving as executive vice president and chief financial officer. The filing confirms he is not a director or 10% owner, and the reported shares are held directly.
Lilly Eli & Co

NYSE:LLY

View LLY Stock Overview

LLY Rankings

LLY Latest News

LLY Latest SEC Filings

LLY Stock Data

801.34B
940.96M
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States
INDIANAPOLIS